NEO-201 and IL-15 Combination Efficacy Data for Endometrial and Ovarian Cancer

A 2026 study by Jamie Hur investigates the combination of monoclonal antibody NEO-201 and cytokine IL-15 to overcome immunotherapy resistance in gynecological cancers. The research includes in vitro experiments on human cancer cell lines and in vivo testing in mice bearing human ovarian cancer. The dataset, shared under a CC-BY-4.0 license, is a 15.7 KB document describing the methodology and results.

Use Cases

• Modeling antibody-dependent cellular cytotoxicity (ADCC) enhancement based on IL-15 and NEO-201 combination data.
• Analyzing in vitro efficacy of immunotherapy combinations against endometrial and ovarian cancer cell lines.
• Studying the role of core 1 O-glycans as a target for monoclonal antibody therapy in cancer.
• Investigating natural killer (NK) cell activity modulation for improving cancer immunotherapy outcomes.

Strengths

• Data is associated with a specific, recent study last updated in March 2026.
• The research includes both in vitro and in vivo experimental components.
• The dataset is openly shared under a permissive CC-BY-4.0 license.

Limitations

• The dataset is a 15.7 KB document, suggesting limited raw experimental data is included.
• Row count and column-level documentation are absent; field semantics must be inferred from the text.
• The description focuses on methodology and results; the availability of structured, machine-readable data is unclear.

Provenance

Source

figshare, authored by Jamie Hur.

Collection Method

Data likely originates from laboratory experiments on human cancer cell lines and mouse models.

Freshness

Last updated 2026-03-17 13:06:55